Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Research & Development of $69.4 million for Q1 2026, up 137.78% sequentially from $29.2 million in Q4 2025, and up 100.88% YoY from $34.5 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Research & Development for 8 years, with the latest figure at $69.4 million in Q1 2026.
- Quarterly Research & Development rose 100.88% year-over-year to $69.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183.6 million (up 19.76% YoY) and the FY2025 annual result came in at $119.5 million, up 7.75% from the prior year.
- Research & Development improved to $69.4 million in Q1 2026 per HRMY's latest filing, from $29.2 million in the prior quarter.
- Over five years, Research & Development peaked at $69.4 million in Q1 2026 and troughed at $5.5 million in Q4 2023.
- A 5-year average of $29.8 million and a median of $27.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development sank 73.69% in 2023, then soared 397.75% in 2024.
- Over 5 years, Research & Development stood at $21.1 million in 2022, then sank by 73.69% to $5.5 million in 2023, then jumped by 397.75% to $27.6 million in 2024, then climbed by 5.72% to $29.2 million in 2025, then soared by 137.78% to $69.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $69.4 million, $29.2 million, and $55.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 46.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.60 Mn |
| Mar 31, 2026 | 69.38 Mn |
| Dec 31, 2025 | 29.18 Mn |
| Sep 30, 2025 | 54.96 Mn |
| Jun 30, 2025 | 30.07 Mn |
| Mar 31, 2025 | 34.54 Mn |
| Dec 31, 2024 | 27.60 Mn |
| Sep 30, 2024 | 27.58 Mn |
| Jun 30, 2024 | 63.58 Mn |
| Mar 31, 2024 | 27.23 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 17.50 Mn |
| Jun 30, 2023 | 24.53 Mn |
| Mar 31, 2023 | 22.57 Mn |
| Dec 31, 2022 | 21.08 Mn |
| Sep 30, 2022 | 20.47 Mn |
| Jun 30, 2022 | 12.67 Mn |
| Mar 31, 2022 | 17.58 Mn |
| Dec 31, 2021 | 19.11 Mn |
| Sep 30, 2021 | 11.74 Mn |